BloodThinnerHelp.com reports today on one of the more notable cases in the Xarelto litigation. This lawsuit was filed in the Xarelto multidistrict litigation in Louisiana by the son of a deceased man from Georgia. The plaintiff’s father passed away due to internal bleeding complications that he alleges were linked to his father’s Xarelto usage. This lawsuit was filed on March 20, 2015 in the United States District Court for the Eastern District of Louisiana under case number 2:15-cv-00886. The full complaint can be downloaded and read here. The plaintiff is a resident of Tennessee and is alleging that Xarelto was the cause of his father’s untimely death.
The complaint details how the plaintiff’s father was initially prescribed Xarelto by his primary care physician to treat a heart condition he suffered from called atrial fibrillation. Xarelto was approved by the FDA to treat atrial fibrillation and the deceased began to take the drug in November 2012. The deceased took the drug until March 2013 when he died due to complications caused by an internal bleeding event. The complaint alleges that this would not have occurred if the plaintiff and his father were made aware of the risks of Xarelto usage before he began to take the drug, asserting that his father would have chosen one of the safer alternatives available on the market.
Lawsuits Allege Xarelto Can Be Life Threatening:
Xarelto is a part of a new class of blood thinners known as Xa inhibitors. Xa inhibitors work differently from traditional blood thinners such as Warfarin because they prevent blood clots by blocking the agent in the blood responsible for making blood clot, thrombin. By blocking thrombin, Xarelto completely takes away the blood’s ability to clot. This is dangerous because Xarelto has no corresponding antidote to reverse its anticoagulant effects, which could lead to uncontrollable internal bleeding events in patients.
The lawsuit filed alleges that the manufacturers of Xarelto had knowledge of the true dangers of Xarelto and deliberately concealed this knowledge. They also allege that the manufacturers did not adequately warn patients and doctors about the irreversible nature of the drug.
Xarelto’s FDA Warnings:
Since Xarelto was approved by the Food and Drug Administration, FDA, in 2011, it has seen high profits due to the marketing tactics of the manufacturers. Since its release though several studies have linked Xarelto to dangerous adverse effects, such as the aforementioned uncontrollable internal bleeding. This has prompted the FDA to attach two black box warnings to Xarelto. The black box warning is the strictest warning the FDA can attach to a drug short of recalling it. It usually means that there is a reasonable risk of harm associated with taking the drug. For the full list of FDA warnings regarding Xarelto, click here.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
###
Contact BloodThinnerHelp.com:
Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.
